View : 301 Download: 0

Impact of GATA4 variants on stable warfarin doses in patients with prosthetic heart valves

Title
Impact of GATA4 variants on stable warfarin doses in patients with prosthetic heart valves
Authors
Jeong, E.Lee, K. E.Jeong, H.Chang, B. C.Gwak, H. S.
Ewha Authors
곽혜선정호철
SCOPUS Author ID
곽혜선scopus; 정호철scopus
Issue Date
2015
Journal Title
PHARMACOGENOMICS JOURNAL
ISSN
1470-269XJCR Link

1473-1150JCR Link
Citation
PHARMACOGENOMICS JOURNAL vol. 15, no. 1, pp. 33 - 37
Publisher
NATURE PUBLISHING GROUP
Indexed
SCIE; SCOPUS WOS scopus
Document Type
Article
Abstract
Interindividual variability in stable warfarin doses is largely attributed to VKORC1 and CYP2C9 variants. On the basis of a recent finding of the role of GATA4 in control of CYP2C9 expression, we tested a possible effect of GATA4 genotypes on variability in warfarin response using 201 Korean patients with prosthetic cardiac valves. Two single-nucleotide polymorphisms (SNPs), rs2645400 (G>T) and rs4841588 (G>T), were significantly associated with stable warfarin doses in patients carrying CYP2C9 wildtype homozygotes; homozygote carriers of these two SNPs required higher doses than those with other genotypes (5.94 +/- 1.73 versus 5.34 +/- 1.88 mg, P = 0.026; 5.94 +/- 1.66 versus 5.37 +/- 1.92, P = 0.036, respectively). Multivariate analysis showed that two GATA4 combinations, rs867858 (G>T)/rs10090884 (A>C) and rs2645400 (G>T)/rs4841588 (G>T), increased contribution to the overall warfarin dose variability from 36.4 to 40.9%. This study revealed that GATA4 can be predictive of stable warfarin dose and extended warfarin pharmacogenetics further to the regulation of CYP2C9 expression.
DOI
10.1038/tpj.2014.36
Appears in Collections:
약학대학 > 약학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

BROWSE